Skip to content
OpenCapital
Get started

Gilead Sciences GILD EPS (Diluted)

EPS (Diluted) at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$1.31+9.2%
Incyte logo
IncyteINCY
$1.47+83.7%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$0.62-313%
Precigen logo
PrecigenPGEN
-$0.02+88.9%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$1.84-43.8%
Sutro Biopharma logo
Sutro BiopharmaSTRO
-$2.94+67.6%

Other financials

Income statement

See full
Revenue$7.0B+4.4%
Gross profit$5.5B+7.6%
Operating income$2.6B+15.6%
Net income$2.0B+53.7%

Balance sheet

See full
Cash & equivalents$7.6B-3.8%
Total debt$22.2B-11.1%
Total equity$23.5B+22.7%
Total assets$56.3B-0.3%

Cash flow

See full
Operating cash flow$2.5B+44.8%
CapEx$117.0M+12.5%
Free cash flow$2.4B+46.8%

Valuation

See full
Market cap$153.76B+13.9%
Enterprise value$168.3B+10.7%
P/E16.7×-5.9×
P/S5.2×+0.5×

Profitability

See full
Gross margin79.4%+1.1pp
Operating margin34.9%+6.3pp
Net margin31%+10.2pp
FCF margin34.4%+0.1pp

Returns & leverage

See full
Return on equity43.2%+10.7pp
Debt / equity0.9×-0.4×
Current ratio2×+0.6×

Where this comes from

Reported directly by Gilead Sciences in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gilead Sciences's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Gilead Sciences's EPS (diluted)?
Gilead Sciences (GILD) reported EPS (diluted) of $1.61 in Q1 2026.
How has Gilead Sciences's EPS (diluted) changed year-over-year?
Gilead Sciences's EPS (diluted) increased by 54.8% year-over-year, from $1.04 to $1.61.
What is the long-term trend for Gilead Sciences's EPS (diluted)?
Over 4 years (2021 to 2025), Gilead Sciences's EPS (diluted) has grown at a 8.3% compound annual growth rate (CAGR), from $4.93 to $6.77.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.